Sentien Biotechnologies is a Boston-based company developing an extracorporeal bioreactor for the treatment of acute kidney injury. Sentien’s lead product supplements dialysis by adding MSC-derived secretions into patients’ blood without directly exposing patients to therapeutic cells. The MSC-derived secretions include a potent mixture of natural anti-inflammatory compounds and trophic molecules that can attenuate the immune dysfunction of acute kidney injury while promoting tissue repair.
Sentien’s device integrates into existing dialysis infrastructure and has shown strong efficacy in preclinical models of acute kidney injury, acute liver injury, and acute myocardial infarction. Portage Biotech and Boehringer Ingelheim Venture Fund participated in a Series A round that, in combination with non-dilutive funding from the National Institute of Health will allow Sentien to finish IND enabling studies and proceed to a Phase I trial in patients. A successful Phase I trial would significantly affect the valuation and could trigger a liquidity event.